Search
Galcanezumab
go.drugbank.com/drugs/DB14042ApprovedInvestigationalGalcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP). … A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060]
Products: EMGALİTY 100 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 3 ADET, EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100 MG/MLFremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigational[L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. … Fremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches.
Products: AJOVY 225 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 3 ADET, AJOVY 225 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETCiclesonide
go.drugbank.com/drugs/DB01410ApprovedInvestigationalCiclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Mixtures: LUXNID 2/200 MCG INHALASYON IÇIN TOZ IÇEREN KAPSÜL,120 KAPSÜL, LUXNID 2/200 MCG INHALASYON IÇIN TOZ IÇIEREN KAPSÜL,60 KAPSÜLCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPralidoxime
go.drugbank.com/drugs/DB00733ApprovedInvestigationalVet approvedIf given within 24 hours,after organophosphate exposure, pralidoxime reactivates the enzyme cholinesterase by cleaving the phosphate-ester bond formed between the organophosphate and acetylcholinesterase
Categories: Compounds used in a research, industrial, or household settingSynonyms: 2-PAMSpiramycin
go.drugbank.com/drugs/DB06145ApprovedInvestigationalWithdrawnSpiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. … Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types
Mixtures: METİRASİN 1,5 MIU/250 MG FILM TABLET, 14 ADET, METİRASİN 1,5 MIU/250 MG FİLM KAPLI TABLET, 10 ADETCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 Enzyme InhibitorsOctinoxate
go.drugbank.com/drugs/DB09496ApprovedInvestigationalIt was originally developed in 1950's as an organic UV-B filter that absorbs UV-B rays from sun. … Its use in pharmaceutical and cosmetic formulations is approved by FDA.
Mixtures: Lovely Me EX 32900042, Lovely ME EX BB PACT SPF20Categories: Compounds used in a research, industrial, or household settingMidostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalMidostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. … It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108].
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersSynonyms: 4'-N-benzoylstaurosporineRanibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigational[A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO. … [L41399] In August 2022, other biosimilars CIMERLI, RAIVISIO, and RANOPTO were approved by the FDA, EC, and Health Canada respectively.[L42625,L43513,L49141]
Products: LUCENTIS® 10 MG /ML SOLUCION INYECTABLE, LUCENTİS 10 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADETInterferon beta-1b
go.drugbank.com/drugs/DB00068ApprovedInvestigationalProduced in E. coli, no carbohydrates, MW=18.5kD
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsProducts: BETAFERON FOR INJECTION 0.25 mg/mlCabotegravir
go.drugbank.com/drugs/DB11751ApprovedInvestigationalCabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, [rilpivirine]. … [A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals.
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingProducts: Vocabria 400 mg/2 ml Enjeksiyonluk Uzatılmış Salımlı Süspansiyon, 1 ADET, Vocabria 600 mg/3 ml Enjeksiyonluk Uzatılmış Salımlı Süspansiyon, 1 ADET